RAPT (STOCKS)
RAPT Therapeutics, Inc. Common Stock
$57.820000
+0.100000 (+0.17%)
Prev close: $57.720000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Brian Russell Wong
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,602.11M
- Employees
- 61
- P/E (TTM)
- -5.22
- P/B (TTM)
- 6.40
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $7.00M |
| Operating Expenses | $112.64M |
| Depreciation and Amortization | $972.00K |
| Research and Development | $82.87M |
| Other Operating Expenses | $28.79M |
| Operating Income/Loss | -$112.64M |
| Income/Loss From Continuing Operations After Tax | -$105.64M |
| Income/Loss From Continuing Operations Before Tax | -$105.64M |
| Net Income/Loss | -$105.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$105.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$105.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $10.67 |
| Diluted Earnings Per Share | $10.67 |
| Basic Average Shares | 62,857,568 |
| Diluted Average Shares | 62,857,568 |
| Assets | $165.74M |
| Current Assets | $161.05M |
| Cash | $157.30M |
| Other Current Assets | $3.75M |
| Noncurrent Assets | $4.69M |
| Fixed Assets | $765.00K |
| Other Non-current Assets | $3.93M |
| Liabilities | $13.76M |
| Current Liabilities | $13.38M |
| Accounts Payable | $2.10M |
| Other Current Liabilities | $11.27M |
| Noncurrent Liabilities | $387.00K |
| Equity | $151.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $151.98M |
| Liabilities And Equity | $165.74M |
| Net Cash Flow From Operating Activities | -$86.58M |
| Net Cash Flow From Operating Activities, Continuing | -$86.58M |
| Net Cash Flow From Investing Activities | -$56.70M |
| Net Cash Flow From Investing Activities, Continuing | -$56.70M |
| Net Cash Flow From Financing Activities | $143.31M |
| Net Cash Flow From Financing Activities, Continuing | $143.31M |
| Net Cash Flow | $30.00K |
| Net Cash Flow, Continuing | $30.00K |
| Comprehensive Income/Loss | -$105.64M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$105.64M |
| Other Comprehensive Income/Loss | -$7.00K |